HLA-I在乳腺癌組織中的表達及其臨床意義_《中國普外基礎與臨床雜志》

作者：

李林卿 ¹ , 莊文欣 ² , 李鵬程 ¹ ,  孫學軍 ¹

1.中國人民解放軍第89醫院普外二科（山東濰坊 261021）;;
2.濰坊醫學院醫學研究實驗中心（山東濰坊 261053）;

關鍵詞：

HLA-I類分子 T細胞免疫抗癌活性乳腺癌

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　研究人類白細胞抗原-I類分子（HLA-I）在乳腺癌組織中的表達及其臨床意義。
方法　采用免疫組織化學方法檢測271例接受乳腺癌手術患者的乳腺癌組織中HLA-I的表達，并分析HLA-I的表達與乳腺癌臨床病理特征及其預后的關系。
結果　271例患者中有92例（33.9%）乳腺癌組織中HLA-I呈強陽性表達，而179例（66.1%）的HLA-I表達下調；乳腺癌組織中HLA-I的表達與腋窩淋巴結轉移、TNM分期、其他淋巴結轉移及血管侵犯均相關（P＜0.05）。HLA-I表達陽性患者的無病生存率明顯高于HLA-I表達下調者（P＜0.05）。
結論　檢測乳腺癌組織中HLA-I的表達情況，對于預測腫瘤進展情況及其預后具有重要意義。

引用本文： 李林卿,莊文欣,李鵬程,孫學軍. HLA-I在乳腺癌組織中的表達及其臨床意義. 中國普外基礎與臨床雜志, 2013, 20(10): 1132-1136. doi: 復制

1.	Cabrera T， Maleno I， Collado A， et al. Analysis of HLA class I alterations in tumors：choosing a strategy based on known patternsof underlying molecular mechanisms[J]. Tissue Antigens， 2007， 69(Suppl 1)：264-268.
2.	Nagorsen D， Thiel E. HLA typing demands for peptide-based anti-cancer vaccine[J]. Cancer Immunol Immunother， 2008， 57(12)：1903-1910.
3.	-microglobulin (beta 2m) with mouse class I major histocompati-bility antigens and its ability to support peptide binding. A comp-arison of human and mouse beta 2m[J]. Eur J Immunol， 1995， 25(6)：1609-1616.
4.	Marincola FM， Jaffee EM， Hicklin DJ， et al. Escape of human solid tumors from T-cell recognition：molecular mechanisms and functional significance[J]. Adv Immunol， 2000， 74：181-273.
5.	Tangri S， Ishioka GY， Huang X， et al. Structural features of peptideanalogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-typepeptide[J]. J Exp Med， 2001， 194(6)：833-846.
6.	Garrido F， Cabrera T， Concha A， et al. Natural history of HLA expression during tumour development[J]. Immunol Today， 1993， 14(10)：491-499.
7.	Garrido F， Ruiz-Cabello F， Cabrera T， et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours[J]. Immunol Today， 1997， 18(2)：89-95.
8.	Hicklin DJ， Marincola FM， Ferrone S. HLA class I antigen downregulation in human cancers：T-cell immunotherapy revives an old story[J]. Mol Med Today， 1999， 5(4)：178-186.
9.	Pedersen LO， Stryhn A， Holter TL， et al. The interaction of beta.
10.	Cabrera T， Angustias Fernandez M， Sierra A， et al. High frequ-ency of altered HLA class I phenotypes in invasive breast carcinomas[J]. Hum Immunol， 1996， 50(2)：127-134.
11.	Tsukahara T， Kawaguchi S， Torigoe T， et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-panHLA class I monoclonal antibody， EMR8-5[J]. Cancer Sci， 2006， 97(12)：1374-1380.
12.	Qifeng S， Bo C， Xingtao J， et al. Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics[J]. J Thorac Cardiovasc Surg， 2011， 141(3)：808-814.
13.	Kikuchi E， Yamazaki K， Torigoe T， et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer[J]. Cancer Sci， 2007， 98(9)：1424-1430.
14.	Kitamura H， Honma I， Torigoe T， et al. Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma[J]. J Urol， 2007， 177(4)：1269-1272.
15.	Ishigami S， Natsugoe S， Nakajo A， et al. HLA-class I expression in gastric cancer[J]. J Surg Oncol， 2008， 97(7)：605-608.
16.	Campoli M， Ferrone S. HLA antigen changes in malignant cells：epigenetic mechanisms and biologic significance[J]. Oncogene， 2008， 27(45)：5869-5885.
17.	de Kruijf EM， Sajet A， van Nes JG， et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognosticvalue for clinical outcome of early breast cancer patients[J]. J Immunol， 2010， 185(12)：7452-7459.
18.	Boomsma MF， Garssen B， Slot E， et al. Breast cancer surgery-induced immunomodulation[J]. J Surg Oncol， 2010， 102(6)：640-648.
19.	de Kruijf EM， van Nes JG， Sajet A， et al. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer[J]. Clin Cancer Res， 2010， 16(4)：1272-1280.
20.	Lavado-Valenzuela R， Benavides M， Carabantes F， et al. MHC class I chain-related gene A transmembrane polymorphism in Spanish women with breast cancer[J]. Tissue Antigens， 2009， 74(1)：46-49.
21.	Torigoe T， Asanuma E， Tamura Y， et al. Establishment of a mono-clonal anti-pan HLA class I antibody suitable for immunostainingof formalin-fixed tissue：unusually high frequency of down-regulation in breast cancer tissues[J]. Pathol Int， 2012， 62(5)：303-308.
22.	Cordon-Cardo C， Fuks Z， Drobnjak M， et al. Expression of HLA-A， B， C antigens on primary and metastatic tumor cell populations of human carcinomas[J]. Cancer Res， 1991， 51(23 Pt 1)：6372-6380.
23.	Madjd Z， Spendlove I， Pinder SE， et al. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer[J]. Int J Cancer， 2005， 117(2)：248-255.
24.	Sato N， Hirohashi Y， Tsukahara T， et al. Molecular pathological approaches to human tumor immunology[J]. Pathology International， 2009， 59(4)：205-217.
25.	Mizukami Y， Kono K， Maruyama T， et al. Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma[J]. Br J Cancer， 2008， 99(9)：1462-1467.
26.	Pistillo MP， Nicolò G， Salvi S， et al. Biochemical analysis of HLA class I subunits expression in breast cancer tissues[J]. Hum Immunol， 2000， 61(4)：397-407.
27.	Zia A， Schildberg FW， Funke I. MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients[J]. Int J Cancer， 2001， 93(4)：566-570.

1. Cabrera T， Maleno I， Collado A， et al. Analysis of HLA class I alterations in tumors：choosing a strategy based on known patternsof underlying molecular mechanisms[J]. Tissue Antigens， 2007， 69(Suppl 1)：264-268.
2. Nagorsen D， Thiel E. HLA typing demands for peptide-based anti-cancer vaccine[J]. Cancer Immunol Immunother， 2008， 57(12)：1903-1910.
3. -microglobulin (beta 2m) with mouse class I major histocompati-bility antigens and its ability to support peptide binding. A comp-arison of human and mouse beta 2m[J]. Eur J Immunol， 1995， 25(6)：1609-1616.
4. Marincola FM， Jaffee EM， Hicklin DJ， et al. Escape of human solid tumors from T-cell recognition：molecular mechanisms and functional significance[J]. Adv Immunol， 2000， 74：181-273.
5. Tangri S， Ishioka GY， Huang X， et al. Structural features of peptideanalogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-typepeptide[J]. J Exp Med， 2001， 194(6)：833-846.
6. Garrido F， Cabrera T， Concha A， et al. Natural history of HLA expression during tumour development[J]. Immunol Today， 1993， 14(10)：491-499.
7. Garrido F， Ruiz-Cabello F， Cabrera T， et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours[J]. Immunol Today， 1997， 18(2)：89-95.
8. Hicklin DJ， Marincola FM， Ferrone S. HLA class I antigen downregulation in human cancers：T-cell immunotherapy revives an old story[J]. Mol Med Today， 1999， 5(4)：178-186.
9. Pedersen LO， Stryhn A， Holter TL， et al. The interaction of beta.
10. Cabrera T， Angustias Fernandez M， Sierra A， et al. High frequ-ency of altered HLA class I phenotypes in invasive breast carcinomas[J]. Hum Immunol， 1996， 50(2)：127-134.
11. Tsukahara T， Kawaguchi S， Torigoe T， et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-panHLA class I monoclonal antibody， EMR8-5[J]. Cancer Sci， 2006， 97(12)：1374-1380.
12. Qifeng S， Bo C， Xingtao J， et al. Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics[J]. J Thorac Cardiovasc Surg， 2011， 141(3)：808-814.
13. Kikuchi E， Yamazaki K， Torigoe T， et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer[J]. Cancer Sci， 2007， 98(9)：1424-1430.
14. Kitamura H， Honma I， Torigoe T， et al. Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma[J]. J Urol， 2007， 177(4)：1269-1272.
15. Ishigami S， Natsugoe S， Nakajo A， et al. HLA-class I expression in gastric cancer[J]. J Surg Oncol， 2008， 97(7)：605-608.
16. Campoli M， Ferrone S. HLA antigen changes in malignant cells：epigenetic mechanisms and biologic significance[J]. Oncogene， 2008， 27(45)：5869-5885.
17. de Kruijf EM， Sajet A， van Nes JG， et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognosticvalue for clinical outcome of early breast cancer patients[J]. J Immunol， 2010， 185(12)：7452-7459.
18. Boomsma MF， Garssen B， Slot E， et al. Breast cancer surgery-induced immunomodulation[J]. J Surg Oncol， 2010， 102(6)：640-648.
19. de Kruijf EM， van Nes JG， Sajet A， et al. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer[J]. Clin Cancer Res， 2010， 16(4)：1272-1280.
20. Lavado-Valenzuela R， Benavides M， Carabantes F， et al. MHC class I chain-related gene A transmembrane polymorphism in Spanish women with breast cancer[J]. Tissue Antigens， 2009， 74(1)：46-49.
21. Torigoe T， Asanuma E， Tamura Y， et al. Establishment of a mono-clonal anti-pan HLA class I antibody suitable for immunostainingof formalin-fixed tissue：unusually high frequency of down-regulation in breast cancer tissues[J]. Pathol Int， 2012， 62(5)：303-308.
22. Cordon-Cardo C， Fuks Z， Drobnjak M， et al. Expression of HLA-A， B， C antigens on primary and metastatic tumor cell populations of human carcinomas[J]. Cancer Res， 1991， 51(23 Pt 1)：6372-6380.
23. Madjd Z， Spendlove I， Pinder SE， et al. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer[J]. Int J Cancer， 2005， 117(2)：248-255.
24. Sato N， Hirohashi Y， Tsukahara T， et al. Molecular pathological approaches to human tumor immunology[J]. Pathology International， 2009， 59(4)：205-217.
25. Mizukami Y， Kono K， Maruyama T， et al. Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma[J]. Br J Cancer， 2008， 99(9)：1462-1467.
26. Pistillo MP， Nicolò G， Salvi S， et al. Biochemical analysis of HLA class I subunits expression in breast cancer tissues[J]. Hum Immunol， 2000， 61(4)：397-407.
27. Zia A， Schildberg FW， Funke I. MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients[J]. Int J Cancer， 2001， 93(4)：566-570.

《中國普外基礎與臨床雜志》

HLA-I在乳腺癌組織中的表達及其臨床意義

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

HLA-I在乳腺癌組織中的表達及其臨床意義

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料